StockIQpro
NYSE:TEVA

Teva Pharmaceutical Industries Ltd.

Track all markets on TradingView
Track all markets on TradingView

Teva Pharmaceutical Industries Ltd.'s revenue grew 4.3% in fiscal 2025 to $17.3B while operating margin rose to 12.5%, its highest in 10 years. Free cash flow was $1.1B, 6.7% of revenue, and the diluted share count rose 2.8%.Summary generated from Teva Pharmaceutical Industries Ltd.'s SEC filings. Latest annual report filed Feb 3, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)$17.3B
Revenue growth+4.3%
Revenue, 5-yr CAGR+0.7%
Gross margin51.8%
Operating margin12.5%
Net margin8.2%
ROICn/a
Return on equity21.2%
Debt / equityn/a
Free cash flow$1.1B
FCF margin6.7%
Share count change+2.8%

Financials

Fiscal years, $B
Item20212022202320242025
Revenue15.914.915.816.517.3
Operating income1.7−2.20.4−0.32.2
Net income0.4−2.4−0.6−1.61.4
Free cash flow0.21.00.80.71.1

Recent filings

From SEC EDGAR

Peers

Pharmaceutical preparations